Table 1.
Main characteristics of the selected studies.
| Trialreference | Drug | Phase no. pts | Histology | PD-L1 | FU time median mo. | HR OS (95% CI) P-value | HR PFS (95% CI) P-value |
|---|---|---|---|---|---|---|---|
| KN-189 (1) | Pembrolizumab ± Platinum-Pem | III 616 |
NonSq | any | 10.5 | 0.49 (0.38–0.64) <0.001 |
0.52 (0.43–0.64) <0.001 |
| KN-021 (2, 3) | Pembrolizumab ± Carbo-Pem | II 123 |
NonSq | any | 10.6 | 0.90 (0.42–1.91) 0.39 |
0.53 (0.31–0.91) 0.010 |
| KN-407a (4) | Pembrolizumab ± Carbo-(nab)Pac | III 559 |
Sq | any | 7.7 | 0.64 (0.49–0.85) 0.0008 |
0.56 (0.45–0.70) <0.0001 |
| IMPower131 (5)a | Atezolizumab ± Carbo-nabPac | III 683 |
Sq | any | 9.8b | 0.96 (0.78–1.18) 0.69 |
0.71 (0.60–0.85) 0.0001 |
| IMPower150 (6) | Atezolizumab ± Carbo-Pac-Beva | III 696 |
NonSq | any | 15.5 | 0.78a (0.64–0.96) P = 0.02 |
0.62 (0.52–0.74) P <0.001 |
| IMPower150bis (7) | Atezolizumab + Carbo-Pac vs. Carbo-Pac-Beva | III 686c |
NonSq | any | 20.0 | NR | 0.88 a (0.72-1.08) 0.20 |
| IMPower132 (8)a | Atezolizumab ± Platinum-Pem | III 578 |
NonSq | any | NR | 0.81 (0.64–1.03) p = 0.08 |
0.60 (0.49–0.72) P <0.0001 |
| IMPower130 (9) | Atezolizumab ± Carbo-nabPac | III 679 |
NonSq | any | 13.0b | 0.79 (0.64–0.98) 0.03 |
0.64 (0.54–0.77) <0.0001 |
| CM-227 (10) | Nivolumab ± Platinum-Pem in NonSq Platinum-Gem in Sq | III 363 |
NonSq (273) Sq (90) |
<1% | 11.2b | NR | 0.74 (0.58–0.94) P = NR |
Beva, bevacizumab; Carbo, carboplatin; CM, Checkmate; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ICPIs, immune-checkpoint inhibitors; CTRT, chemo-radiotherapy; FU, follow-up; KN, Keynote; mo., months; NonSq, non-squamous; NR, not reported; NSCLC, non-small cell lung cancer; Pem, pemetrexed; Pac, paclitaxel; Sq, squamous; vs. versus.
a
Results refer to first interim analysis.
b
Minimum follow-up.
c
Carbo-Pac-Beva arm was the same of the above mentioned trial and included 337 patients.